Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.98,832 enrolled

Overview

Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years. Are men prescribed a PDE5 inhibitor for ED more likely to have a new diagnosis of underlying medical conditions compared to men of a similar age not receiving PDE5 inhibitor treatment?

Study Type

OBSERVATIONAL

Enrollment

98,832

Conditions

Erectile Dysfunction Cardiovascular Diseases Male Urogenital Diseases

Interventions

no interventionOTHER

non-interventional study

no interventionOTHER

non-interventional study

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Records of men aged \>18 years with an index PDE5 inhibitor (sildenafil, tadalafil or vardenafil) prescription between January 1st, 1999, and June 30th, 2008 * no prior PDE5 inhibitor prescription before the index prescription * continuous enrolment with medical history for ≥60 months prior to the index prescription date Exclusion Criteria: * Records of female subjects and any male subjects not meeting the inclusion criteria will be excluded * A subject can only be selected once independent of the assignment to the target or the control populations.

Outcomes

Primary Outcomes

Percentage of Participants With Underlying Condition Until Day -1 of the Index PDE5i Prescription

Underlying conditions were defined as any diagnosis of interest recorded in the relevant time period. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Time frame: Day -92 up to Day -1 of index prescription

Cumulative Percentage of Participants With New Diagnosis of Underlying Condition Between Index PDE5i Prescription (Day 0) and Day 91

New diagnosis of underlying condition at prescription was defined as any new diagnosis of interest recorded in the relevant time period. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Time frame: Day 0 to Day 91 post index prescription

Percentage of Participants With New Diagnosis of Underlying Condition Between Day -92 and Day -1 Prior to the Index PDE5i Prescription

New diagnosis of underlying condition was defined as any new diagnosis of interest recorded in the relevant time period. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Time frame: Day -92 up to Day -1 of index prescription

Percentage of Participants With New Diagnosis of Underlying Condition Between Day 366 and Day 457 Post the Index PDE5i Prescription

Time frame: Day 366 up to Day 457 post index prescription

Percentage of Participants With Underlying Condition at PDE5i Market Introduction During the Early Study Period

Underlying condition at PDE5i market introduction was defined as any diagnosis of interest until day -1 in participants who received the index prescription between January 1, 1999 and December 31, 2001 for the three years period combined. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Percentage of Participants With New Diagnosis of Underlying Condition at PDE5i Market Introduction During the Early Study Period

New diagnosis of underlying condition at PDE5i market introduction was defined as any new diagnosis of interest until day -1 in participants who received the index prescription between January 1, 1999 and December 31, 2001 for the three years period combined. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Time frame: Up to 3 years (Early study period - January 1999 to December 2001)

Percentage of Participants With Underlying Condition at PDE5i Establishment During the End of Study Period

Underlying condition at PDE5i market introduction was defined as any diagnosis of interest until day -1 in participants who received the index prescription between July 1, 2006 and June 30, 2008 for the two years period combined. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Time frame: Up to 2 years (End of study period - July 2006 to June 2008)

Percentage of Participants With New Diagnosis of Underlying Condition at PDE5i Establishment During the End of Study Period

New diagnosis of underlying condition at PDE5i establishment was defined as any new diagnosis of interest between day 0 (index prescription) and day 91 in participants who received the index prescription between July 1, 2006 and June 30, 2008 for the two-years period combined. Diagnoses of interest were coded and categorized in to vasculogenic, urologic, neurogenic, hormonal, drug induced and psychogenic disorders.

Time frame: Up to 2 years (End of study period - July 2006 to June 2008)